BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25675183)

  • 1. A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases.
    Simons M; Nagtegaal ID; Overbeek LI; Flucke U; Massuger LF; Bulten J
    Int J Gynecol Pathol; 2015 Mar; 34(2):143-50. PubMed ID: 25675183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
    Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
    Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.
    Riopel MA; Ronnett BM; Kurman RJ
    Am J Surg Pathol; 1999 Jun; 23(6):617-35. PubMed ID: 10366144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
    Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
    Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression in ovarian borderline tumors and stage I carcinomas.
    Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
    Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of CA125 immunoreactivity in recurrent or metastatic primary ovarian mucinous neoplasms of the intestinal type.
    Miller K; Millar J; McCluggage WG
    Am J Surg Pathol; 2011 Sep; 35(9):1331-6. PubMed ID: 21836488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian mucinous borderline tumors of intestinal type without intraepithelial carcinoma: are they still tumors of low malignant potential?
    Nomura K; Aizawa S; Hano H
    Pathol Int; 2004 Jun; 54(6):420-4. PubMed ID: 15144401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion?
    Kim KR; Lee HI; Lee SK; Ro JY; Robboy SJ
    Am J Surg Pathol; 2007 Apr; 31(4):546-54. PubMed ID: 17414101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
    Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
    Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic problems of ovarian mucinous borderline tumors].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Jun; 53(2):127-33. PubMed ID: 19581178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucinous tumor of low malignant potential ("borderline" or "atypical proliferative" tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion.
    Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Siriaunkgul S
    Int J Gynecol Pathol; 2011 May; 30(3):218-30. PubMed ID: 21464732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
    Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
    Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.